News

TB R&D Weekly Update: Early bactericidal activity of OPC-67683

Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54.

This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity.

The results reported are from the Phase IIa Early Bactericidal Activity (EBA) study which evaluates a drug candidates short-term potency when given as a single drug and at different doses. These studies are now generally 14-days and look at the log reduction of colony forming units (CFU) of M. tuberculosis in sputum collections from patients.

Highlights from the article are:

  • 54 patients were randomized with 96% completing study treatment. The two patients that did not complete treatment were withdrawn on day one of treatment due to protocol violation and insufficient sputum production.
  • 4 doses were evaluated: 100 mg, 200 mg, 300 mg, 400 mg. For first 2 days averaging all dosages, the EBA was similar to rifabutin, streptomycin and amikacin; higher than pyrazinamide; and lower than isoniazid, ethambutol, linezolid, rifampin and rifapentine. A greater proportion of patients achieved a reduction in CFU of ≥0.9 log10 in the 200 mg and 300 mg treatment arms compared to 100 mg.
  • The was no apparent dose response with plasma concentrations plateauing at 300 mg. It was noted that delamanid is poorly soluble in water and has limited absorption at higher dosages.
  • Results were optimistic and delamanid is currently undergoing evaluation in MDR-TB patients.

Additional TB R&D News Updates:

Report–New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Incidence of Moxifloxacin Resistance in Clinical Mycobacterium tuberculosis Isolates in Houston, Texas

Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania

Herbal TB Immunotherapy to be Presented at Hong Kong Conference

More News
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...
23 Mar 2022
On March 21st, 2022, the World Health Organization (WHO) updated its guidelines on treatment of non-severe TB disease in children and adolescents. The new guidelines recommend a shorter duration of treatment and reduces the standard of care which is currently 6 months of therapy down to 4 months...